Nucliq Biologics is a microbiome health company building the future of personalized diagnostics and therapeutics—starting with the gut. Our flagship products, GutCheck (DTC) and GutCheck Vivo (B2B), deliver microbiome-powered insights to individuals and clinics, helping manage conditions linked to gut and hormonal imbalances. With commercial traction in India and early B2B interest in North America, we’re now focused on scaling sales and marketing to grow market share in both geographies. What sets Nucliq apart is our roadmap beyond testing: we’re building an AI-driven platform to mine microbiome data for novel microbial signatures and small molecules—paving the way for microbiome-based therapeutics targeting the gut-brain axis. We're raising capital to scale revenue from GutCheck, grow strategic partnerships through GutCheck Vivo, and accelerate development of our AI-powered discovery engine.